Biovica Provides Update on FDA Application Process
UPPSALA, SE / ACCESSWIRE / September 13, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)
Biovica, active in cancer diagnostics, today announced that the company's expected timeline for its updated 510(k)-application to the US Food and Drug Administration (FDA) has been prolonged due to delay in response from FDA.
As Biovica is still waiting for required feedback from the FDA the company has not been able to submit its updated application yet. This means that the company most likely will not receive an answer from the FDA before the end of September, as previously communicated.
After submitting the response to the FDA, the expected outcome is either approval (clearance) or a request to submit more information.
"It is of course unfortunate that the FDA process is delayed. It is caused by the pandemic situation and unfortunately out of our control. We are ready to submit updates to the application but need to have patience and understanding about how the pandemic situation has affected processing times at the FDA. Thankfully, this is a short-term obstacle that will be overcome in due time," said Anders Rylander.
Anders Rylander, CEO
Phone: +46-18-444 48 35
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medical Products Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, firstname.lastname@example.org , +46 8 528 00 399. For more information please visit: www.biovica.com .
This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-09-13 08:07 CEST.
SOURCE: Biovica International
View source version on accesswire.com:
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Smart Eye23.9.2021 20:17:05 CEST | Press release
Notice to Attend the Extraordinary General Meeting in Smart Eye Aktiebolag (publ)
XVIVO Perfusion AB23.9.2021 09:31:49 CEST | Press release
XVIVO Capital Markets Day Presents Strategic Focus Areas for 2022-2026
Biovica International23.9.2021 08:21:34 CEST | Press release
Notice of Extra General Meeting in Biovica International AB
AlzeCure Pharma22.9.2021 14:20:11 CEST | Press release
AlzeCure Presents at Naventus Life Science Summit on September 29
Pacific Green Technologies Inc.21.9.2021 15:02:25 CEST | Press release
Pacific Green Signs Offer for Debt Finance for Its First Battery Energy Storage Development at Richborough Energy Park
Gungnir Resources Inc.21.9.2021 12:01:56 CEST | Press release
Gungnir Drills 6.67% Nickel Within 5.65 metres Grading 2.62% Nickel
Loop Industries, Inc.20.9.2021 06:02:25 CEST | Press release
Evian Unveils 100% rPET Bottles Created by Loop Industries’ Innovative Recycling Technology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom